| Project/Area Number |
15K20230
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | National Center for Global Health and Medicine (2016-2018)
Showa University (2015) |
|---|
Principal Investigator |
WATANABE SO 国立研究開発法人国立国際医療研究センター, その他部局等, 耳鼻いんこう科医長 (20439491)
|
|---|
| Research Collaborator |
HINOHIRA YASUYUKI
PAWANKAR RUBY
|
|---|
| Project Period (FY) |
2015-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | アレルギー性鼻炎 / マイクロバイオーム / 微生物ゲノム / microbiome |
|---|
| Outline of Final Research Achievements |
Both microbes and allergens can stimulate the nasal mucosa, potentially affecting the disease state of allergic rhinitis (PAR). We hypothesized that sinonasal microbiome of PAR patients can differ from the one of normal control. Microbiota specimens were obtained by nasal endoscopy from the nasal cavity of both PAR patients and normal controls. Samples were analyzed by next-generation sequencing. Serum samples were collected simultaneously and cytokine protein levels were analyzed by ELISA. Operational Taxonomic Unit (OTU) of PAR patients were not significantly different from the one of controls, though cytokine levels were significantly higher in patients group. Comparison of the genus level has not been completed yet, so further evaluation should be needed.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回の検討では検出された鼻腔内細菌の総数は患者群と健常者群で変化がなく、これはアレルギー性鼻炎により血中Th2サイトカインが高値であっても、少なくとも細菌の属のレベルにはあまり影響が生じないものと推測された。残念ながら菌種レベルでの比較検討がまだ完了しておらず、得られたデータを元にさらに解析を行うことが必要と考えられた。おそらくは菌種レベルでの健常者との違いが見いだせると予想され、ここで見られるであろう菌種の差が今後のアレルギー性鼻炎の新たな治療の鍵になるのではないかと期待される。
|
